論文

査読有り
2022年1月5日

Salivary Metabolomics for Prognosis of Oral Squamous Cell Carcinoma

Frontiers in Oncology
  • Shigeo Ishikawa
  • ,
  • Masahiro Sugimoto
  • ,
  • Tsuneo Konta
  • ,
  • Kenichiro Kitabatake
  • ,
  • Shohei Ueda
  • ,
  • Kaoru Edamatsu
  • ,
  • Naoki Okuyama
  • ,
  • Kazuyuki Yusa
  • ,
  • Mitsuyoshi Iino

11
開始ページ
789248
終了ページ
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.3389/fonc.2021.789248
出版者・発行元
Frontiers Media SA

This study aimed to identify salivary metabolomic biomarkers for predicting the prognosis of oral squamous cell carcinoma (OSCC) based on comprehensive metabolomic analyses. Quantified metabolomics data of unstimulated saliva samples collected from patients with OSCC (n = 72) were randomly divided into the training (n = 35) and validation groups (n = 37). The training data were used to develop a Cox proportional hazards regression model for identifying significant metabolites as prognostic factors for overall survival (OS) and disease-free survival. Moreover, the validation group was used to develop another Cox proportional hazards regression model using the previously identified metabolites. There were no significant between-group differences in the participants’ characteristics, including age, sex, and the median follow-up periods (55 months [range: 3–100] <italic>vs.</italic> 43 months [range: 0–97]). The concentrations of 5-hydroxylysine (p = 0.009) and 3-methylhistidine (p = 0.012) were identified as significant prognostic factors for OS in the training group. Among them, the concentration of 3-methylhistidine was a significant prognostic factor for OS in the validation group (p = 0.048). Our findings revealed that salivary 3-methylhistidine is a prognostic factor for OS in patients with OSCC.

リンク情報
DOI
https://doi.org/10.3389/fonc.2021.789248
URL
https://www.frontiersin.org/articles/10.3389/fonc.2021.789248/full
ID情報
  • DOI : 10.3389/fonc.2021.789248
  • eISSN : 2234-943X

エクスポート
BibTeX RIS